FTSE 100 news / Companies and sectors / GSK
GSK news analysis
GSK (LSE: GSK) is in the FTSE 100. 21 of the last 21 days had relevant coverage.
Latest: Tuesday 20 October 2026
+8.3 from 37 relevant stories. Coverage was dominated by FDA approval of Jemperli for a type of rectal cancer, alongside promising early lung cancer data for ris-rez. Analyst support from Jefferies and an $800M US manufacturing investment added to the positive lean.
Tone over time
Coverage of GSK held broadly steady between 30 September 2026 and 20 October 2026
Daily news tone, from −10 (clearly bad) to +10 (clearly good). Gaps are days with no relevant stories.
Tone fell 3.9% from 9 to 8 between 30 Sep and 20 Oct. Its low was −3 in 3 Oct.
- 11
- 22
- 33
3 days of 21 had fewer than 3 relevant stories, so those points are thin evidence. Numbered markers are the days with the strongest single headline (key below). This is the tone of coverage, not a share price.Source: MarketFrame news analysis
| day | Tone |
|---|---|
| 30 Sep | 9 |
| 1 Oct | 5 |
| 2 Oct | 2 |
| 3 Oct | −3 |
| 4 Oct | 7 |
| 5 Oct | 6 |
| 6 Oct | 5 |
| 7 Oct | 8 |
| 8 Oct | 6 |
| 9 Oct | 2 |
| 10 Oct | 7 |
| 11 Oct | 8 |
| 12 Oct | 8 |
| 13 Oct | 7 |
| 14 Oct | 2 |
| 15 Oct | 1 |
| 16 Oct | 1 |
| 17 Oct | 2 |
| 18 Oct | 1 |
| 19 Oct | 9 |
| 20 Oct | 8 |
Day by day
| Day | Tone | Stories | What the coverage was about |
|---|---|---|---|
| Tuesday 20 October 2026 | +8.3 | 37 | Coverage was dominated by FDA approval of Jemperli for a type of rectal cancer, alongside promising early lung cancer data for ris-rez. |
| Monday 19 October 2026 | +8.5 | 7 | Coverage was mainly about positive early-stage lung cancer data for Ris-Rez, with a 61% response rate reported. |
| Sunday 18 October 2026 | +0.7 | 2 | Coverage was thin, limited to a profile of chief executive Luke Miels and a routine note on the share price ahead of the next Xetra session. |
| Saturday 17 October 2026 | +2.0 | 10 | Coverage was mixed. |
| Friday 16 October 2026 | +0.8 | 16 | Coverage was split between plans to cut up to 1,217 jobs in Belgium, with union blockades, and positive items such as an $800M US manufacturing hub, executive share purchases and a share price gain. |
| Thursday 15 October 2026 | +1.3 | 34 | Coverage was split between GSK's $800 million Pennsylvania manufacturing investment, along with supportive analyst views and a share price rise, and reports of up to 1,217 job cuts in Belgium under its restructuring. |
| Wednesday 14 October 2026 | +2.3 | 20 | Coverage centred on the Pennsylvania manufacturing expansion and routine insider dividend reinvestments, plus previews of the third-quarter results. |
| Tuesday 13 October 2026 | +7.2 | 16 | Coverage was dominated by GSK's $800 million Pennsylvania biomanufacturing and R&D expansion, alongside an expanded AI drug discovery deal with Chai Discovery. |
| Monday 12 October 2026 | +8.0 | 8 | Coverage centred on GSK's $800 million-plus expansion in Pennsylvania's Montgomery County, with over 300 new jobs and biologics manufacturing. |
| Sunday 11 October 2026 | +7.5 | 3 | Coverage centred on an $800 million GSK investment bringing 300 jobs, which reads well for the company. |
| Saturday 10 October 2026 | +6.8 | 19 | Coverage was dominated by GSK's plan to invest more than $800 million in Pennsylvania, creating over 300 jobs. |
| Friday 9 October 2026 | +2.0 | 21 | Coverage was dominated by GSK's Viola Davis shingles campaign, plus positive news on ViiV's HIV trial and a blood-cancer acquisition. |
| Thursday 8 October 2026 | +5.7 | 16 | Coverage focused on GSK adding new pipeline candidates through partnerships and licensing, including a liver drug and a Chimagen myeloma drug. |
| Wednesday 7 October 2026 | +7.7 | 11 | Coverage was mainly about positive late-stage trial results for ViiV's long-acting HIV treatment Cabenuva, alongside a potential USD 750 million multiple myeloma deal and the Nuvalent agreement. |
| Tuesday 6 October 2026 | +4.7 | 6 | Coverage was mildly positive, led by a Health Canada review of Jemperli for rectal cancer, a ViiV investment in paediatric HIV response and discussion of the Nuvalent acquisition as a growth prospect. |
| Monday 5 October 2026 | +6.0 | 5 | Coverage centred on GSK's dealmaking, including a completed USD 2.3 billion acquisition and a $750 million myeloma therapy purchase, which adds to its pipeline. |
| Sunday 4 October 2026 | +7.0 | 1 | Coverage centred on GSK agreeing to acquire the ChImagen therapy for $750 million. |
| Saturday 3 October 2026 | −3.0 | 1 | Coverage was thin, with the only relevant story saying a voting rights update pressured GSK's share price near a resistance level. |
| Friday 2 October 2026 | +1.7 | 12 | Coverage mixed pipeline progress, including a liver candidate from the Wave partnership and a reported Nuvalent deal, with the completed Haleon exit. |
| Thursday 1 October 2026 | +5.0 | 20 | Coverage was mostly positive, centred on GSK's progress with Wave's siRNA liver programme, continued Gates funding for TB research and a Jefferies view that its cancer pipeline is undervalued. |
| Wednesday 30 September 2026 | +8.7 | 7 | Coverage was mostly positive, led by Jefferies keeping its buy rating and Berenberg setting a 2,200p target, with attention on the B7H3 cancer programme. |
Sector: Pharma and healthcare